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A phase II trial was performed to determine the antitumour efﬁcacy and tolerance of combined paclitaxel and cisplatin with or
without hematopoetic growth factor support in patients with advanced gastric cancer. Forty-ﬁve patients with histologically
conﬁrmed metastatic gastric cancer were entered in this trial. Treatment consisted of 2-weekly courses of paclitaxel 160 mg
per m
2 and cisplatin 60 mg per m
2 both given on day 1. Depending on absolute neutrophil counts on the days of scheduled
chemotherapeutic drug administration (1000–2000 per ml), a 5-day course of human granulocyte colony-stimulating factor
5 mgk g
71 per day was given subcutaneously; in addition, if haemoglobin was 512.0 mg dl
71, erythropoietin 10000 IU was
administered subcutaneously three times per week. The conﬁrmed overall response rate (intent-to-treat) was 44%, including
ﬁve complete (11%) and 15 partial remissions (33%). Twelve patients had stable disease (27%), 11 (24%) progressed while on
chemotherapy, and two patients were not evaluable. The median time to response was 3 months, the median time to
progression 7.0 months, and the median survival time was 11.2 months with 12 patients currently alive. Haematologic toxicity
was common, though WHO grade 4 neutropenia occurred in only ﬁve patients (11%). Apart from total alopecia in 16
patients (36%), severe non-haematologic adverse reactions included grade 3 peripheral neuropathy in six (13%) and
anaphylaxis in two patients. In addition, there was one patient each who experienced grade 3 emesis, diarrhea, and infection,
respectively. Our data suggest that the combination of paclitaxel and cisplatin with or without G-CSF and/or erythropoietin
has promising therapeutic activity in patients with advanced gastric cancer.
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Despite its declining incidence in the Western world, gastric cancer
is still amongst the most common malignancies (Landis et al,
1998). Cytotoxic chemotherapy has been widely used in patients
with advanced or metastatic gastric cancer and has been demon-
strated to be effective in the palliative management of this
disease. In randomised trials, in fact, a signiﬁcant improvement
in overall survival and in quality of life was noted when compared
to best supportive care alone (Pyrhonen et al, 1995; Scheithauer et
al, 1995; Glimelius et al, 1997). Although several second generation
combination regimens that have been developed in the 1980s–
including epirubicin/adriamycin/cispatin (EAP), ﬂuorouracil/adria-
mycin/methotrexate (FAMTX), etoposide/leukovorin/ ﬂuorouracil
(ELF), and infusional ﬂuorouracil/cisplatin (FUP)–were reported
to result in rather high objective response rates, randomised trials
have generally failed to reproduce these data and thus demonstrate
a substantial change in the natural course of advanced disease
(Wils, 1996; Fuchs, 1997). Only the ECF-regimen (epirubicin,
cisplatin and infusional ﬂuorouracil) showed a superior response
rate (46% vs 21%) and prolonged survival (8.9 vs 5.7 months)
compared with FAMTX (Webb et al, 1997), and thus made it a
sort of standard chemotherapy. Still, the identiﬁcation of new
agents and/or drug combinations with a superior therapeutic index
remains a principal goal of investigational efforts. Because
chemotherapy use in patients with disseminated disease, who fare
particularly poorly, is aimed at producing palliative effects, the
anticancer activity and side effects must be weighted carefully.
The results of recently published trials in patients with metastatic
gastric carcinomas have suggested that both cisplatin and paclitaxel
are relatively active and well tolerated drugs. Cisplatin has been
used in the treatment of gastric cancer in the neoadjuvant, adju-
vant and palliative setting and various combination regimens
have been reported to show response rates between 20–71%
(Findlay et al, 1994; Wils, 1996; Morant, 2001). Paclitaxel is a novel
antineoplastic drug with the unique cytotoxic mechanism of tubu-
lin stabilisation and polymerisation (Arbuck, 1994). It has
demonstrated broad clinical activity in a variety of malignancies
both alone and in combination regimens. Antitumour activity of
paclitaxel also has been shown in gastric cancer cell lines and in
several phase I/II trials (Arbuck, 1994; Bokemeyer et al, 1997;
Murad et al, 1999; Kollmannsberger et al, 2000; Safran et al,
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www.bjcancer.combeing the dose-limiting toxicity and patients receiving this agent
can be treated on an outpatient basis.
Favourable results were obtained when both drugs were
combined in patients with ovarian cancer, advanced non-small cell
lung cancer (NSCLC), head and neck- and oesophageal carcinomas
(Ilson et al, 1998; Khuri et al, 2000; Gatzemeier et al, 2000; Pﬁs-
terer, 2000). Furthermore, two recently published phase II
studies, investigating the combination of cisplatin with docetaxel,
a semisynthetic taxoid, suggested a high antitumour activity with
an overall response rate of 37 and 56%, respectively (Roth et al,
2000; Ridwelski et al, 2001).
The aim of the present study was thus to evaluate the antitumour
activity and tolerance of paclitaxel plus cisplatin in chemotherapy-
naive patients with disseminated gastric cancer. To minimise acute
toxicities and counteract myelosuppression that was likely to consti-
tute the dose-limiting toxicity with this combination, we decided to
use a biweekly administration schedule of paclitaxel and cisplatin.
A potentially improved therapeutic index despite dose inteniﬁcation
by using fractionated, i.e., weekly or biweekly drug dose regimens has
been reported in other malignancies, including NSCLC (Brunn, 1997;
Soerensen et al, 1997). The particular dose regimen used in this trial
was based on the results of a previous phase I study in patients with
advanced oesophageal cancer (van der Gaast et al, 1997). In addition,
to maintain the planned dose intensity, granulocyte colony-stimulat-
ing factor (G-CSF) was given depending on absolute neutrophil
counts on the days of scheduled chemotherapeutic drug administra-
tion. Since recent data suggest that erythropoietin, apart from its
ability to potentiate the effect of G-CSF, signiﬁcantly improves qual-
ity of life in cancer patients receiving cisplatin and non-platinum
chemotherapy with a possible beneﬁcial effect in terms on overall
survival, we decided to co-administer this haematopoetic growth
factor in patients with haemoglobin levels below 12 mg mL
71 (Pier-
elli et al, 1999; Littlewood, 2001).
PATIENTS AND METHODS
Patients selection
Patients eligible for this study had histologically conﬁrmed
advanced gastric cancer (except carcinomas of the oesophagastric
junction) with bidimensionally measurable disease not previously
treated with palliative chemotherapy and not amenable to curative
resection. All patients were required to be 75 years old or younger,
to have a World Health Organisation (WHO) performance status
of less than 3, to have an expected survival time of more than
12 weeks, and to have adequate bone marrow (absolute neutrophil
count (ANC) 52.000 per mL, and platelet count 5100000 per
mL), adequate renal (serum creatinine concentration 5132 mmol,
creatinine clearance 570 ml min
71 as calculated by the Calvert
formula), and adequate hepatic function (bilirubin and serum
transaminase level 52 times the upper limit of normal). Patients
were ineligible if they had a history of prior or concomitant malig-
nancy, except for curatively treated nonmelanoma skin cancer or in
situ cervical cancer. Female patients could not be pregnant or
lactating. A prior history of atrial or ventricular arrhythmias and/
or history of congestive heart failure, even when medically
controlled, disqualiﬁed patients from study entry. Pre-existing
motor or sensory neurologic symptoms 5WHO grade 2 were
not allowed, nor were active infections or other serious underlying
medical conditions that would impair the ability of the patient to
receive protocol treatment. All patients gave written informed
consent according to institutional regulations.
Treatment protocol
Chemotherapy consisted of paclitaxel (Taxol
1, Bristol-Myers
Squibb Company, Princeton, NJ, USA) 160 mg per m
2, dissolved
in 500 ml of normal saline and given as a 3 h infusion plus
cisplatin 60 mg per m
2, diluted in 500 ml normal saline and
administered as 1 h infusion. Pre- and post-hydration with at
least 2000 ml of intravenous ﬂuid (normal saline or 5% dextrose
per 24 h) were mandatory. The recommended prophylactic anti-
emetic medication consisted of dexamethasone and 5-hydroxy-
tryptamine-3 antagonists. Before paclitaxel administration, each
patient received premedication including dexamethasone (20 mg
orally, 12 and 6 h before paclitaxel), cimetidine (300 mg i.v.,
30 min before paclitaxel), and diphenhydramine (50 mg i.v.,
30 min before paclitaxel). Treatment courses were repeated every
2 weeks, and were to be continued in patients achieving
complete or partial remission or stabilisation of disease for a
total of 12 courses. Depending on absolute neutrophil counts
on the days of scheduled chemotherapeutic drug administration
(1000–2000 per mL), a 5-day course of human granulocyte
colony-stimulating factor (G-CSF, Neupogen
1, Amgen Europe,
Netherlands) 5 mgk g
71 per day was given. In addition, if
haemoglobin was 512.0 mg dl
71 erythropoietin 10000 IU
(ERYPO
1, Janssen-Cilag Pharma, Austria) was administered s.c.
three times per week until a haemoglobin level 413.5 mg dl
71
has been reached.
Toxicity and dosage modiﬁcation guidelines
Adverse reactions were evaluated according to WHO standard
criteria. Treatment could be delayed for up to 2 weeks if the
ANC was lower than 1000 per mL and/or platelet count was lower
than 75000 per mL. Prolonged administrations of G-CSF (until the
neutrophil count was 52000 per mL) was recommended in the
former group of patients. Drug doses were reduced by 25% in case
of febrile neutropenia grade 4, if the lowest platelet count was less
than 25000 per mL, in case of grade 1 nephrotoxicity or grade 2
neuropathy, or if any severe (4WHO grade 2) non-haematologic
toxicity was observed in the previous cycle. Paclitaxel was stopped
in any case of grade 4 skin toxicity and grade 3 anaphylactic reac-
tion. Both chemotherapeutic drugs were discontinued in the event
of transitory 5 grade 2 renal toxicity or deﬁnitive decrease of crea-
tinine clearance (560 ml min
71), 5 grade 3 neuropathy, and if
severe toxicity recurred despite dose attenuation. Similarly, any
patient who required more than 2 weeks for full recovery of
adverse reactions (except alopecia and mild neuropathy) was taken
off study.
Pretreatment and follow-up evaluation
Pretreatment evaluation included a complete medical history and
physical examination, routine haematology and biochemistry
analyses, ECG, chest X-ray, and CT scans to deﬁne the extent of
disease. Complete blood counts and differential counts were
obtained weekly, and biochemical proﬁles were assessed before each
treatment cycle. Measurable lesions were reassessed every 8 weeks
by CT scan, X-ray, or any other technique that allows retrospective
and independent evaluation.
Assessment of response
The primary efﬁcacy endpoint of this trial was objective response
rate, which was evaluated according to WHO standard criteria.
In addition, complete remission (CR) of the primary tumour site
was deﬁned as a normal appearing stomach on CT-scan with
complete resolution of the endoscopically visible tumour and a
negative biopsy of the original site of the tumour. All tumour
measurements were reviewed and conﬁrmed by an independent
panel of radiologists and oncologists. Secondary efﬁcacy endpoints
included the duration of response (measured from the onset of the
best response to the date of disease progression), time to progres-
sion (calculated from the start of therapy to the time of
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An ‘optimal two-stage design’ was chosen for this phase II trial
(Gehan, 1961). If fewer than four responses were noted in the ﬁrst
17 eligible patients, accrual would be halted. Because responses
were observed, additional patients were enrolled to a ﬁnal accrual
of 45 patients to better estimate efﬁcacy and characterise the toxi-
city proﬁle. This sample size was considered sufﬁcient to estimate
95% conﬁdence intervals for the true response rate with a maxi-
mum width of 30%. For the response rate, 95% conﬁdence
intervals were calculated as previously described (Anderson et al,
1985). The distribution of time to death from the time of study
entry was estimated by using the Kaplan–Meier product-limit
method (Kaplan and Meier, 1958). All patients who were enrolled
onto the study were included in the intent-to-treat analysis.
RESULTS
Patient characteristics
Between January 1999 and November 2000, a total of 45 patients
took part in this trial. All of them were evaluable for toxicity
and 43 patients for response assessment. Two patients who were
considered non-measurable by the external review committee, were
kept in the ﬁnal intent-to-treat analysis of response. The demo-
graphic data, sites of metastatic tumour, and previous therapies
are listed in Table 1. The median age of the 13 female and 32 male
patients was 59 years (range, 35 to 75 years), and the median
WHO performance status was 1 (range, 0–2). Except for 13
patients, all had multiple metastases involving two or more organ
systems. Twenty-nine patients (64%) had disseminated disease at
the time of ﬁrst diagnosis, 13 of whom required palliative surgical
interventions. The remaining 16 patients had metastatic disease
recurrence after having undergone previous potential curative
resection; the median interval from initial diagnosis to relapse
was 11 (range, 3 to 131) months in these patients.
A total of 398 courses of study treatment were administered to
the 45 patients. The median number of treatment cycles was 10
(range, 2 to 12), and the median duration of follow-up at the time
of this analysis was 17 (range, 6–29) months.
Response to treatment
The overall response rate was 44.4% (95% conﬁdence interval, 29.7
to 60.0%), including ﬁve (11.1%) complete and 15 (33.3%) partial
remissions; the median duration of response was 6.5 months
(range, 3 to 17 months). Twelve additional patients (26.6%) had
disease stabilisation, and 11 (24.5%) progressed while on treat-
ment. The median time to disease progression was 7 months
(range, 1 to 20) and the median survival was 11.2 months (range,
1.5 to 21+) with 12 patients (26.7%) still being alive after a median
follow-up time of 14 months. Sixteen patients, who failed paclitax-
el/cisplatin or experienced tumour progression within 6 months
after completion of chemotherapy, received second-line therapy.
The most frequently used second-line regimens were ﬂuorouracil/
leucovorin plus etoposide (n=4) or epirubicin (n=5), and oxalipla-
tin/raltitrexed in seven patients.
Toxicity
Side effects associated with treatment are listed in Tables 2 and 3.
Myelosuppression was the most commonly encountered toxicity,
although according to the ANC-adapted use of G-CSF, the time
to WBC/ANC recovery was generally short: 95% of the episodes
of leukopenia/neutropenia were resolved within 7 days. Adminis-
tration of G-CSF because of ANCs of 1000 to 2000 per mLo n
the day of scheduled chemotherapeutic drug administration, as
indicated in the protocol, was effected in 26 patients (58%), after
a median of 6 courses (range, 1 to 12). A total of 59 5-day courses
of G-CSF were given with most of the patients (73%) receiving
fewer than three courses. Leukocytopenia occurred in 39 patients
(87%), and was grade 3 or 4 in ﬁve (11%) and two (4%) patients.
Neutropenia was also observed in 39 cases (87%), and was grade 3
or 4 in 10 (22%) and ﬁve patients (11%), respectively. Five patients
(11%) developed documented infection, one of whom required
hospitalisation for intravenous antibiotics. Anaemia was commonly
observed (69%) and was grade 3 in two patients (4%). Twenty-two
patients (49%) received erythropoietin because their pretreatment
haemoglobin value was or dropped below 12.0 mg dl
71 during
chemotherapy and 17 of them (77%) responded to this haemato-
poetic growth factor support. Grade 1 or 2 thrombocytopenia
was seen in only three patients.
Nonhaematologic adverse reactions are listed in Table 3. Gastro-
intestinal symptoms were the most frequently encountered
toxicities. Nausea and vomiting occurred in 21 patients (47%),
symptoms however, were generally mild or moderate (grade 1, 2
or 3 in 24, 20 or 2%, respectively) and responsive to standard
antiemetic therapy. Diarrhoea was noted in nine patients (20%)
and was grade 3 in only one case. Constipation occurred in ﬁve
patients, and grade 1 or 2 stomatitis in four. Twenty-two patients
(49%) developed peripheral neuropathy, including 6 (13%) who
experienced severe (WHO grade 3) symptoms. Two patients
(4%) developed anaphylactic reactions despite adequate premedica-
tion. Skin reactions and nail changes were seen in two patients
each, and minor ﬂuid retention in six. Alopecia was noted in a
total of 30 patients (67%), 16 of who had complete hair loss. Asth-










































Number of involved organs
Single 13
Multiple 32
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British Journal of Cancer (2002) 86(12), 1858–1863 ã 2002 Cancer Research UKand renal function were observed in one (2%) and 10 (22%)
patients, respectively.
Drug exposure
The dose of both chemotherapeutic drugs was reduced in three
patients due to (febrile) grade 4 neutropenia and in two patients
because of (grade 1) nephrotocixity; dose modiﬁcations of paclitax-
el according to progressive peripheral neuropathy were required in
ﬁve additional patients. Fifteen patients (33%) had at least one
treatment delay of 1 week at some time during therapy, and the
total number of delayed courses was 29 (14%). The reasons for
delayed courses were haematologic toxicity in 20 cases, neutropenic
fever in four, transiently impaired renal function in one, deteriora-
tion in performance status in two, and personal reasons in two
patients. Treatment was discontinuated prematurely in two patients
because of anaphylaxis, in four patients due to grade 3 peripheral
neuropathy (after six to 10 treatment courses), in one case because
of intercurrent upper gastrointestinal tract bleeding, and in two
additional patients for personal reasons.
Dose-intensity was calculated for each patient and for each drug.
The mean given dose-intensity of the combination was 92% of the
projected dose. The mean delivered dose of paclitaxel per week was
73.6 mg per m
2 (range, 59.2 to 80 mg per m
2) and the mean deliv-
ered dose of cisplatin per week was 27.6 mg per m
2 (range, 22.2 to
30 mg per m
2).
DISCUSSION
The continuing lack of substantial progress in the treatment of
advanced gastric cancer, particularly in patients with poor perfor-
mance status or compromised organ function, who are unlikely
to tolerate potentially active but toxic regimens, has prompted
investigators to evaluate new agents and/or drug combinations
including docetaxel, paclitaxel, and irinotecan (Bokemeyer et al,
1997; Boku et al, 1999; Murad et al, 1999; Kollmannsberger et al,
2000; Roth et al, 2000; Ridwelski et al, 2001).
The present study, to our knowledge, is the ﬁrst to report
mature results on the efﬁcacy and safety with the combination of
paclitaxel plus cisplatin in patients with advanced gastric cancer.
The rationale for their combined use were: (1) the documented
activity of both drugs in gastric cancer when used as single agent
(Wils, 1996); (2) the apparent synergistic efﬁcacy and safety of this
combination in patients with ovarian-, head and neck cancer, and
NSCLC (Ilson et al, 1998; Gatzemeier et al, 2000; Khuri et al, 2000;
Pﬁsterer, 2000); (3) as well as the encouraging results of two
recently published reports of a combination of cisplatin and the
semisynthetic taxoid docetaxel (Roth et al, 2000; Ridwelski et al,
2001).
With an intent-to treat response rate of 44%, including 11%
complete remissions, a median progression free interval of 7
months, and median overall survival of 11.2 months, the results
of the present multicenter phase II investigation suggest a marked
antitumour activity of this combination in patients with metastatic
gastric cancer. The non-randomised phase II study design, as we
have learned in the past, does not allow to draw any ﬁrm conclu-
sion nor any direct comparison with other regimens. In fact, other
drug combinations with even higher objective response rates than
observed in the present study have been described in the past,
and have failed to show superiority in subsequent phase III trials
(Kelsen et al, 1998; Vanhoefer et al, 2000). Therefore, results must
be interpreted with caution, and warrant conﬁrmation in a rando-
mised trial setting. Still, the observed antitumour potential, which
is in agreement with the previously mentioned phase II studies of
Roth et al (2000) (RR 56%, median survival 9 months), and
Ridwelski et al (2001) (RR 37%, median survival 10.4 months),
suggests that taxane/cisplatin-based combination chemotherapy
might be as active as second- or even third-generation regimens
including ECF or the more intense and toxic PELF (Cascinu et
al, 1997; Webb et al, 1997). Potential advantages of the described
biweekly and other taxane+cisplatin combination regimens are
related to the non-requirement of a central venous access and
external infusional devices with their associated risks and costs
(Lemmers et al, 1996; Kock et al, 1998).
As it concerns the tolerance of treatment, neutropenia was a
commonly encountered adverse reaction associated with this regi-
men, and WHO grade 3 or 4 toxicity occurred in 15 patients
(33%). Due to the actual ANC-adapted use of G-CSF, however,
only 20 of 398 courses (5%) had to be delayed for haematologic
toxicity reasons, and there was a low rate of febrile neutropenic
episodes with only one patient requiring hospitalisation. The rather
high rate/incidence of anaemia in our patient population was prob-
ably not only caused by therapy, but also inﬂuenced by the
underlying malignant disease. Twenty-two patients received recom-
binant human erythropoietin according to the protocol and 17 of
them (77%) responded to the haematopoetic growth factor
support. In as much reversing anaemia in these patients has
contributed to the favourable study outcome can not be deter-
mined. Clinical trials, however, have shown that correcting
anaemia not only provides an objective improvement in the
patients’ well being, but may also improve response and possibly
the duration of survival (Littlewood, 2001; Littlewood et al, 2001).
Apart from anaphylactic reactions in two patients and grade 3
peripheral neurotoxicity in six, nonhaematologic adverse reactions
were generally mild to moderate and fully reversible. Despite use/
realisation of a high dose intensity of both chemotherapeutic drugs,
in addition to a lower rate of neutropenia, also certain nonhaema-
tologic toxicities such as arthralgia/myalgia, asthenia and
gastrointestinal symptoms were less commonly seen when
compared to other phase II/III studies of this particular drug
combination in other disease entities (McGuire et al, 1996; Rose
et al, 1999; Gatzemeier et al, 2000). Similarly, in the advanced









Table 2 Highest grade of haematologic toxicity experienced (n=45)
Grade 1 Grade 2 Grade 3 Grade 4
Number Number Number Number
Toxicity (%) (%) (%) (%)
Leukocytopenia 15 (33) 17 (38) 5 (11) 2 (4)
Neutropenia 7 (15) 17 (38) 10 (22) 5 (11)
Anaemia 15 (33) 14 (31) 2 (4) –
Thrombocytopenia 2 (4) 1 (2) – –
Table 3 Highest grade of nonhaematologic toxicity experienced (n=45)
Grade 1 Grade 2 Grade 3 Grade 4
number number number number
Toxicity (%) (%) (%) (%)
Nausea/vomiting 11 (24) 9 (20) 1 (2) –
Diarrhoea 4 (8) 4 (8) 1 (2) –
Stomatitis 3 (6) 1 (2) – –
Constipation 3 (6) 2 (4) – –
Peripheral neuropathy 5 (11) 11 (24) 6 (13) –
Anaphylaxis – – 2 (4) –
Alopecia 6 (13) 8 (18) 16 (36) –
Fluid retention 4 (8) 2 (4) – –
Asthenia 16 (35) 3 (6) – –
Renal impairment 6 (13) 4 (8) – –
Liver enzymes 1 (2) – – –
Infection 1 (2) 3 (6) 1 (2) –
Conjunctivitis 1 (2) – – –
Skin/nail reaction 1 (2) 1 (2) – –
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per m
2 once every 3 weeks, a much higher rate of severe haemato-
toxicity (up to 57% of patients experienced grade 4 neutropenia),
and grade 3 gastrointestinal adverse reactions (which occurred in
about 9% in both trials) was noted.
In conclusion, the results of this trial indicate that the
described biweekly combination regimen of paclitaxel plus
cisplatin+G-CSF and/or erythropoietin is an effective and toler-
able regimen for disseminated gastric cancer. It seems to have
durable antitumour activity with an acceptable level of both
haematologic and other organ toxicities. Compared with previous
phase II/III investigations of this combination in other malignan-
cies, the incidence of severe neutropenia as well as of certain
other nonhaematologic adverse reactions seems to be lower.
The difference might be explained by the ANC-adapted use of
G-CSF+erythropoietin, the choice of the taxane, and/or the
biweekly chemotherapeutic drug administration schedule. In view
of the promising therapeutic index of the described regimen,
further evaluation of this combination in patients with advanced
disease as well as in the neoadjuvant setting, seems warranted. In
these and/or other clinical trials in patients with gastric cancer
receiving cytotoxic chemotherapy, it might also be of particular
interest to try to deﬁne precisely the impact of correcting anae-
mia with erythropoietin in terms of quality of life and
therapeutic outcome.
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